by Peter Ciszewski | Dec 28, 2020
Thanos Zomas, MD, from Takeda Oncology, discusses 5-year follow-up data from the ECHELON-2 study presented at ASH 2020. The ECHELON-2 study was a double-blind, randomized, multicenter, phase 3 clinical trial that finished in 2018. It compared the efficacy and...
by Peter Ciszewski | Dec 26, 2020
Roberto Salvatori, MD, Medical Director, Johns Hopkins Pituitary Center and Professor of Medicine at Johns Hopkins discusses acromegaly guidelines and treatment options, which include surgical removal of the adenoma, radiotherapy, or pharmacological reduction of...
by Peter Ciszewski | Dec 25, 2020
Andrew Kuykendall, MD, Assistant Member at Moffitt Cancer Center in the Department of Malignant Hematology gives an overview of polycythemia vera. As Dr. Kuykendall explains, polycythemia vera is a rare blood disorder characterized by an increased...
by Peter Ciszewski | Dec 24, 2020
Hagop Kantarjian, MD, from The University of Texas MD Anderson Cancer Center, discusses data on the efficacy and safety of ponatinib in chronic-phase chronic myeloid leukemia (CML) patients. This data was presented at ASH 2020. CML is a rare blood cancer...
by Peter Ciszewski | Dec 24, 2020
Mehrdad Mobasher, MD, MPH, Chief Medical Officer at Corvus Pharmaceuticals, discusses the latest research with CPI-818 for treating autoimmune lymphoproliferative syndrome (ALPS). ALPS is a rare pediatric genetic disorder that results in lymphadenopathy,...
